Влияние внутреннего подтипа на эффективность терапии ингибиторами CDK4/6 при распространенном HR+/HER2раке молочной железы
- Авторы: Гречухина К.С.1, Филоненко Д.А.1, Сухова М.В.1, Жукова Л.Г.1
-
Учреждения:
- ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы
- Выпуск: Том 26, № 2 (2024)
- Страницы: 182-189
- Раздел: Статьи
- URL: https://journals.rcsi.science/1815-1434/article/view/260600
- DOI: https://doi.org/10.26442/18151434.2024.2.202748
- ID: 260600
Цитировать
Полный текст
Аннотация
В настоящее время в рутинной клинической практике используют классификацию рака молочной железы (РМЖ) по иммуногистохимическим фенотипам. Однако генетический профиль опухоли не всегда соответствует патоморфологическому, что может значимо влиять на прогноз и предсказывать эффективность терапии при РМЖ. В статье рассмотрена эффективность эндокринотерапии в зависимости от внутреннего подтипа РМЖ, а также представлены данные об эффективности ингибиторов CDK4/6 в данных подгруппах. Показано, что в процессе метастазирования опухоль приобретает более агрессивный подтип (например, переходит из люминального в HER2-E или базальноподобный), что может быть остановлено при применении терапии ингибиторами CDK4/6, при назначении которых внутренний подтип переходит в более благоприятную группу.
Полный текст
Открыть статью на сайте журналаОб авторах
Катерина Сергеевна Гречухина
ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы
Автор, ответственный за переписку.
Email: dr.grechukhina@gmail.com
ORCID iD: 0000-0002-0616-5477
канд. мед. наук, ст. науч. сотр., врач-онколог
Россия, МоскваДарья Александровна Филоненко
ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы
Email: dr.grechukhina@gmail.com
ORCID iD: 0000-0002-7224-3111
канд. мед. наук, зав. дневным стационаром по онкологическому профилю
Россия, МоскваМаргарита Витальевна Сухова
ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы
Email: dr.grechukhina@gmail.com
ORCID iD: 0009-0004-7119-0160
врач-онколог дневного стационара по онкологическому профилю
Россия, МоскваЛюдмила Григорьевна Жукова
ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы
Email: dr.grechukhina@gmail.com
ORCID iD: 0000-0003-4848-6938
чл.-кор. РАН, д-р мед. наук, зам. дир. по онкологии
Россия, МоскваСписок литературы
- Russnes HG, Lingjærde OC, Børresen-Dale AL, Caldas C. Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters. Am J Pathol. 2017;187(10):2152-62. doi: 10.1016/j.ajpath.2017.04.022
- Cejalvo JM, Pascual T, Fernández-Martínez A, et al. Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. Cancer Treat Rev. 2018;67:63-70. doi: 10.1016/j.ctrv.2018.04.015
- Prat A, Chaudhury A, Solovieff N, et al. Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. J Clin Oncol. 2021;39(13):1458-67. doi: 10.1200/JCO.20.02977
- Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-7. doi: 10.1200/JCO.2008.18.1370
- Paquet ER, Hallett MT. Absolute assignment of breast cancer intrinsic molecular subtype. J Natl Cancer Inst. 2015;107(1):357. doi: 10.1093/jnci/dju357
- Turner NC, Liu Y, Zhu Z, et al. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. J Clin Oncol. 2019;37(14):1169-78. doi: 10.1200/JCO.18.00925
- Finn RS, Liu Y, Zhu Z, et al. Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. Clin Cancer Res. 2020;26(1):110-21. doi: 10.1158/1078-0432.CCR-19-0751
- Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688-98. doi: 10.1158/1078-0432.CCR-14-0432
- Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011;24(2):157-67. doi: 10.1038/modpathol.2010.200
- Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. doi: 10.1038/nature11412
- Cejalvo JM, Martínez de Dueñas E, Galván P, et al. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. Cancer Res. 2017;77(9):2213-21. doi: 10.1158/0008-5472.CAN-16-2717
- Godoy-Ortiz A, Sanchez-Muñoz A, Chica Parrado MR, et al. Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications. Front Oncol. 2019;9:1124. doi: 10.3389/fonc.2019.01124
- Prat A, Carey LA, Adamo B, et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst. 2014;106(8). doi: 10.1093/jnci/dju152
- Ferrari A, Vincent-Salomon A, Pivot X, et al. A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. Nat Commun. 2016;7:12222. doi: 10.1038/ncomms12222
- Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82. doi: 10.1126/science.3798106
- Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist. 2002;7(Suppl. 4):2-8. doi: 10.1634/theoncologist.7-suppl_4-2
- Polyak K. Heterogeneity in breast cancer. J Clin Invest. 2011;121(10):3786-8. doi: 10.1172/JCI60534
- Kim HK, Park KH, Kim Y, et al. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance. Cancer Res Treat. 2019;51(2):737-47. doi: 10.4143/crt.2018.342
- Cheang MC, Martin M, Nielsen TO, et al. Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist. 2015;20(5):474-82. doi: 10.1634/theoncologist.2014-0372
- Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366-73. doi: 10.1200/JCO.2011.35.0868
- Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744-52. doi: 10.1200/JCO.2014.55.5730
- Perez EA, Ballman KV, Mashadi-Hossein A, et al. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial. J Natl Cancer Inst. 2017;109(2). doi: 10.1093/jnci/djw207
- Prat A, Parker JS, Fan C, et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol. 2012;23(11):2866-73. doi: 10.1093/annonc/mds080
- Lesurf R, Griffith OL, Griffith M, et al. Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial. Ann Oncol. 2017;28(5):1070-7. doi: 10.1093/annonc/mdx048
- Prat A, Cheang MC, Galván P, et al. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. JAMA Oncol. 2016;2(10):1287-94. doi: 10.1001/jamaoncol.2016.0922
- Prat A, Brase JC, Cheng Y, et al. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. Oncologist. 2019;24(7):893-900. doi: 10.1634/theoncologist.2018-0407
- Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtypeACOSOG Z1031. J Clin Oncol. 2011;29(17):2342-9. doi: 10.1200/JCO.2010.31.6950
- Brasó-Maristany F, Palafox M, Monserrat L, et al. 16P Understanding the biologic determinants of ribociclib efficacy in breast cancer. Ann Oncol. 2021;32:21-36. doi: 10.1016/j.annonc.2021.03.030
- Portman N, Alexandrou S, Carson E, et al. Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. Endocr Relat Cancer. 2019;26(1):R15-30. doi: 10.1530/ERC-18-0317
- Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77-106. doi: 10.1016/j.gendis.2018.05.001
- Witkiewicz AK, Cox D, Knudsen ES. CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer. 2014;5(7-8):261-72. doi: 10.18632/genesandcancer.24
- Piezzo M, Cocco S, Caputo R, et al. Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors. Int J Mol Sci. 2020;21(18). doi: 10.3390/ijms21186479
- Zhang J, Bu X, Wang H, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553(7686):91-5. doi: 10.1038/nature25015
- Laphanuwat P, Jirawatnotai S. Immunomodulatory Roles of Cell Cycle Regulators. Front Cell Dev Biol. 2019;7:23. doi: 10.3389/fcell.2019.00023
- Chaikovsky AC, Sage J. Beyond the Cell Cycle: Enhancing the Immune Surveillance of Tumors Via CDK4/6 Inhibition. Mol Cancer Res. 2018;16(10):1454-7. doi: 10.1158/1541-7786.MCR-18-0201
- Finn R, Liu Y, Martin M, et al. Abstract P2-09-10: Comprehensive gene expression biomarker analysis of CDK 4/6 and endocrine pathways from the PALOMA-2 study. Cancer Res. 2018;78:P2-09-10. doi: 10.1158/1538-7445.SABCS17-P2-09-10
- Carey L, Solovieff N, Andre F, O’Shaughnessy J. GS2-00. Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2advanced breast cancer. San Antonio Breast Cancer Symposium. San Antonio, Texas. 2021.
- Prat A, Chaudhury A, Solovieff N, et al. Abstract GS1-04: Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies. San Antonio Breast Cancer Symposium. San Antonio, Texas. 2020.
- Jacobson A. Ribociclib Improves Overall Survival in HR+/HER2Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes. Oncologist. 2022;27(Suppl. 1): S11-2. doi: 10.1093/oncolo/oyac010
- Martínez OS, Tolosa P, Sánchez De Torre A, et al. 23P CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): a retrospective analysis of real-world data. Ann Oncol. 2021;32:21-36. doi: 10.1016/j.annonc.2021.03.037
- Pascual T, Stover DG, Thuerigen A, et al. 272TiP HARMONIA SOLTI-2101 / AFT-58: A head-to-head phase III study comparing ribociclib (RIB) and palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC). Ann Oncol. 2022;33:S662. doi: 10.1016/j.annonc.2022.07.1856
- Jørgensen CLT, Larsson AM, Forsare C, et al. PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications. Cancers (Basel). 2021;13(7). doi: 10.3390/cancers13071592
- Prat A, Saura C, Pascual T, et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):33-43. doi: 10.1016/S1470-2045(19)30786-7